glimepiride has been researched along with Cardiac Failure in 9 studies
glimepiride: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effect of left ventricular ejection fraction (LVEF) on the behavior of N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in patients with heart failure and type 2 diabetes mellitus with the use of canagliflozin compared to glimepiride." | 9.69 | Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial. ( Eguchi, K; Kitada, S; Kodama, K; Node, K; Ohte, N; Seo, Y; Takeishi, Y; Tanaka, A; Teragawa, H; Yamada, T, 2023) |
| "Our findings suggest that 24 weeks of treatment with canagliflozin, relative to glimepiride, reduced WBC counts in patients with type 2 diabetes and heart failure." | 9.51 | Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial. ( Imai, T; Matsunaga, K; Minamino, T; Nakamura, I; Node, K; Ozaki, Y; Sata, M; Shimabukuro, M; Tanaka, A, 2022) |
| "A total of 250 patients with type 2 diabetes who are drug-naïve or taking any anti-diabetic agents and suffering from chronic heart failure with a New York Heart Association classification I to III will be randomized centrally into either canagliflozin or glimepiride groups (1: 1) using the dynamic allocation method stratified by age (<65, ≥65 year), HbA1c level (<6." | 9.22 | Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. ( Ako, J; Anzai, T; Eguchi, K; Inoue, T; Kitakaze, M; Murohara, T; Node, K; Oyama, J; Saito, Y; Sakata, Y; Sata, M; Sato, Y; Shimizu, W; Suzuki, M; Taguchi, I; Tanaka, A; Tomiyama, H; Ueda, S; Uematsu, M; Watada, H; Yamashina, A, 2016) |
| "This study was a post hoc analysis of the CANDLE trial (UMIN000017669), which compared the effect of 24 weeks of treatment with canagliflozin or glimepiride for changes in N-terminal pro-brain natriuretic peptide in patients with T2DM and chronic heart failure (CHF)." | 8.31 | Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial. ( Ajioka, M; Hiramitsu, S; Imai, T; Kadokami, T; Node, K; Shimabukuro, M; Suzuki, M; Takahashi, N; Tanaka, A; Yamaguchi, S, 2023) |
| "To investigate the effect of left ventricular ejection fraction (LVEF) on the behavior of N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in patients with heart failure and type 2 diabetes mellitus with the use of canagliflozin compared to glimepiride." | 5.69 | Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial. ( Eguchi, K; Kitada, S; Kodama, K; Node, K; Ohte, N; Seo, Y; Takeishi, Y; Tanaka, A; Teragawa, H; Yamada, T, 2023) |
| "Our findings suggest that 24 weeks of treatment with canagliflozin, relative to glimepiride, reduced WBC counts in patients with type 2 diabetes and heart failure." | 5.51 | Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial. ( Imai, T; Matsunaga, K; Minamino, T; Nakamura, I; Node, K; Ozaki, Y; Sata, M; Shimabukuro, M; Tanaka, A, 2022) |
| "A total of 250 patients with type 2 diabetes who are drug-naïve or taking any anti-diabetic agents and suffering from chronic heart failure with a New York Heart Association classification I to III will be randomized centrally into either canagliflozin or glimepiride groups (1: 1) using the dynamic allocation method stratified by age (<65, ≥65 year), HbA1c level (<6." | 5.22 | Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. ( Ako, J; Anzai, T; Eguchi, K; Inoue, T; Kitakaze, M; Murohara, T; Node, K; Oyama, J; Saito, Y; Sakata, Y; Sata, M; Sato, Y; Shimizu, W; Suzuki, M; Taguchi, I; Tanaka, A; Tomiyama, H; Ueda, S; Uematsu, M; Watada, H; Yamashina, A, 2016) |
| "This study was a post hoc analysis of the CANDLE trial (UMIN000017669), which compared the effect of 24 weeks of treatment with canagliflozin or glimepiride for changes in N-terminal pro-brain natriuretic peptide in patients with T2DM and chronic heart failure (CHF)." | 4.31 | Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial. ( Ajioka, M; Hiramitsu, S; Imai, T; Kadokami, T; Node, K; Shimabukuro, M; Suzuki, M; Takahashi, N; Tanaka, A; Yamaguchi, S, 2023) |
| "In participants with type 2 diabetes, the incidences of microvascular complications and death were not materially different among the four treatment groups." | 3.11 | Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. ( Bebu, I; Burch, HB; Buse, JB; Cherrington, AL; Fortmann, SP; Green, JB; Kahn, SE; Kirkman, MS; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Phillips, LS; Pop-Busui, R; Steffes, M; Tiktin, M; Tripputi, M; Wexler, DJ; Younes, N, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 6 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Tanaka, A | 6 |
| Imai, T | 2 |
| Shimabukuro, M | 2 |
| Nakamura, I | 1 |
| Matsunaga, K | 1 |
| Ozaki, Y | 1 |
| Minamino, T | 1 |
| Sata, M | 2 |
| Node, K | 6 |
| Nathan, DM | 1 |
| Lachin, JM | 1 |
| Bebu, I | 1 |
| Burch, HB | 1 |
| Buse, JB | 1 |
| Cherrington, AL | 1 |
| Fortmann, SP | 1 |
| Green, JB | 1 |
| Kahn, SE | 1 |
| Kirkman, MS | 1 |
| Krause-Steinrauf, H | 1 |
| Larkin, ME | 1 |
| Phillips, LS | 1 |
| Pop-Busui, R | 1 |
| Steffes, M | 1 |
| Tiktin, M | 1 |
| Tripputi, M | 1 |
| Wexler, DJ | 1 |
| Younes, N | 1 |
| Yamaguchi, S | 1 |
| Hiramitsu, S | 1 |
| Takahashi, N | 1 |
| Kadokami, T | 1 |
| Ajioka, M | 1 |
| Suzuki, M | 2 |
| Ohte, N | 2 |
| Kitada, S | 2 |
| Yamada, T | 2 |
| Eguchi, K | 3 |
| Teragawa, H | 2 |
| Takeishi, Y | 2 |
| Kodama, K | 2 |
| Seo, Y | 2 |
| Nakatani, D | 1 |
| Dohi, T | 1 |
| Hikoso, S | 1 |
| Nanasato, M | 1 |
| Shimizu, W | 2 |
| Sakata, Y | 2 |
| Zhao, C | 1 |
| Jiang, X | 1 |
| Peng, L | 1 |
| Zhang, Y | 1 |
| Li, H | 1 |
| Zhang, Q | 1 |
| Wang, Y | 1 |
| Yang, F | 1 |
| Wu, J | 1 |
| Wen, Z | 1 |
| He, Z | 1 |
| Shen, J | 1 |
| Chen, C | 1 |
| Wang, DW | 1 |
| Inoue, T | 1 |
| Kitakaze, M | 1 |
| Oyama, J | 1 |
| Taguchi, I | 1 |
| Watada, H | 1 |
| Tomiyama, H | 1 |
| Ako, J | 1 |
| Anzai, T | 1 |
| Uematsu, M | 1 |
| Yamashina, A | 1 |
| Saito, Y | 1 |
| Sato, Y | 1 |
| Ueda, S | 1 |
| Murohara, T | 1 |
| Andersson, C | 1 |
| Gislason, GH | 1 |
| Jørgensen, CH | 1 |
| Hansen, PR | 1 |
| Vaag, A | 1 |
| Sørensen, R | 1 |
| Mérie, C | 1 |
| Olesen, JB | 1 |
| Weeke, P | 1 |
| Schmiegelow, M | 1 |
| Norgaard, ML | 1 |
| Køber, L | 1 |
| Torp-Pedersen, C | 1 |
| Skugor, M | 1 |
| Siraj, ES | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study[NCT01794143] | Phase 3 | 5,047 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for glimepiride and Cardiac Failure
4 other studies available for glimepiride and Cardiac Failure
| Article | Year |
|---|---|
Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hyperinsulinism; H | 2023 |
Glimepiride, a novel soluble epoxide hydrolase inhibitor, protects against heart failure via increasing epoxyeicosatrienoic acids.
Topics: Animals; Eicosanoids; Epoxide Hydrolases; Heart; Heart Failure; Humans; Mice | 2023 |
Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus; Female; Glipizide; Glyburide; Heart Failure; Humans; Hyp | 2011 |
A diabetic woman with worsening heart failure, hunger, and tremor.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Gastrointestinal Agents; Heart Failure; Humans; Hy | 2003 |